Clinical trials: Disease Attributes
Pulmonary Disease, Chronic Obstructive, Cigarette Smoking
E-Visit for COPD and Smoking Cessation
The goal of this work is to develop, refine, and pilot test an electronic visit (e-visit) to: 1) deliver smoking cessation treatment to adults at risk for COPD and 2) to improve rates of COPD early detection and accurate…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Cigarette Smoking, Telemedicine
- Trial name
- NCT04155073
- Testing
- smoking cessation, early COPD detection, electronic visit, Treatment As Usual
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Medical University of South Carolina
Long COVID, Long Covid19
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT05965739
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Background: Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers.
- Conditions
- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
- Trial name
- NCT06865677
- Testing
- Sacituzumab Govitecan, EKG, Brain MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Kidney Disease, Diabetes
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress…
- Trial name
- NCT01350388
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Cough, Chronic Disease
Internet-Behavioral Cough Suppression Therapy
The goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an Internet-based behavioral intervention for refractory chronic cough.
- Trial name
- NCT05770401
- Testing
- Internet-Behavioral Cough Suppression Therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Montana
Follicular Lymphoma, Small Lymphocytic Lymphoma
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma…
- Trial name
- NCT02258529
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Hodgkin Lymphoma
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, mocetinostat and brentuximab vedotin, is in treating cancer.
- Trial name
- NCT02429375
- Testing
- Mocetinostat Plus Brentuximab Vedotin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anemia, Chronic Kidney Disease
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
This study will evaluate the efficacy and safety of intravenous MK2578, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving erythropoietin stimulating…
- Trial name
- NCT00924781
- Testing
- MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline, MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline, MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Anaemia
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in…
- Trial name
- NCT01977482
- Testing
- GSK1278863, rhEPO
- Where
- 107 sites in United States, Australia and 14 more
- Volunteers
- 216 people
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV)…
- Trial name
- NCT01254643
- Testing
- V503
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Cardiovascular Disease
Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
There has been an exponential growth in the number of people with Chronic Kidney Disease (CKD) needing dialysis or transplantation, increasing from 209,000 in 1991 to 472,000 in 2004.
- Trial name
- NCT00897715
- Testing
- Rilonacept
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Chronic Lymphocytic Leukemia
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control.
- Trial name
- NCT01539291
- Testing
- Idelalisib
- Where
- 45 sites in United States, France and 3 more
- Volunteers
- 161 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease (COPD)
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00615459
- Testing
- Indacaterol, Tiotropium
- Where
- 20 sites in Australia, Germany and 5 more
- Volunteers
- 169 people
- Sponsor
- Novartis
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD.
- Trial name
- NCT00909779
- Testing
- Arformoterol
- Where
- 73 sites in United States
- Volunteers
- 841 people
- Sponsor
- Sumitomo Pharma America, Inc.
Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma…
- Trial name
- NCT05498220
- Testing
- Polatuzumab vedotin (PV), Rituximab, Hyaluronidase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients categorized as high-risk CLL has a poor clinical outcome when treated with conventional…
- Conditions
- B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphatic
- Trial name
- NCT03204188
- Testing
- Ibrutinib, Fludarabine, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.